Xiaofeng Chen

Title: Innovations of Xiaofeng Chen in Metabolic Disease Treatment

Introduction

Xiaofeng Chen is a notable inventor based in Dongguan, China, recognized for his contributions to the field of biotechnology. He has been instrumental in developing innovative solutions aimed at treating metabolic diseases. With a total of two patents to his name, Chen's work focuses on enhancing the efficacy of fusion proteins.

Latest Patents

Xiaofeng Chen's latest patents include "Dual-target fusion proteins comprising FGF21 and GLP-1, connected through a Fc portion of an immunoglobulin." This patent describes a fusion protein that contains GLP-1 and FGF21 linked through an immunoglobulin Fc portion. Each of the GLP-1 and FGF21 can be substituted with their analogues or variants, and the Fc portion, which can be derived from IgG4, can include substitutions that enhance the fusion protein's stability and activity. These fragments can be linked together through peptide linkers. The fusion protein is designed for clinical applications to reduce glucose and lipid levels and body weight. Another significant patent is "FGF21 variant, fusion protein and application thereof," which details a fibroblast growth factor 21 (FGF21) variant that significantly improves binding ability with the target and can be used to treat metabolic diseases.

Career Highlights

Xiaofeng Chen works at Sunshine Lake Pharma Co., Ltd., where he continues to innovate in the field of metabolic disease treatment. His research and development efforts have positioned him as a key player in the biotechnology sector.

Collaborations

Chen collaborates with talented individuals such as Chao Chen and Shushan Lin, contributing to a dynamic research environment that fosters innovation.

Conclusion

Xiaofeng Chen's work in developing fusion proteins represents a significant advancement in the treatment of metabolic diseases. His innovative patents and collaborations highlight his commitment to improving healthcare solutions.